EMEPELLE, the first and only skincare range clinical proven1 to help address skin affected by menopause, is giving hope to women with accelerated skin ageing. It helps rejuvenate, restore and rebalance oestrogen-deficient skin caused by menopause.
Oestrogen loss is a primary cause of accelerated collagen loss and skin ageing in women. Emepelle is uniquely powered by MEP Technology, a patented, specifically designed ingredient that helps to non-hormonally restore the natural function of oestrogen deficient skin.
Emepelle is the latest line in the Biopelle skincare range, an international leader in advanced skincare. It was launched at the 2019 American Academy of Dermatology (AAD) meeting in Washington DC, and has since gone on to win an Elle Furture of Beauty Award for innovation in skincare. Thankfully, it’s now available in Ausytralia and New Zealand, distributed exclusively by Dermocosmètica and available in select medical clinics.
“We are thrilled to announce the introduction of Emepelle for women with skin affected by menopause, a condition that affects millions of women in Australia,” said George Kypreos Managing Director and Founder of Dermocosmètica. “At this time, there are no cosmeceuticals available that are clinically proven to safely and effectively help address symptoms of menopausal skin. We are excited that there is finally a product that can empower women and help them manage the ageing process of their skin more confidently.”
The role of oestrogen in skin ageing
Oestrogen is critical to maintaining healthy, radiant, youthful looking skin. As women age, oestrogen levels naturally decline. Although women may notice skin dryness or changes to the condition of their skin as they get older, they likely do not make the correlation with declining oestrogen levels. Low oestrogen results in skin dryness, atrophy, wrinkling and thinning. In the first five years of menopause low oestrogen levels lead to a staggering 30% loss of the skin’s collagen and a subsequent 2.1% loss each year thereafter.2
Emepelle features exclusive MEP Technology to help restore the natural function of oestrogen deficient skin non-hormonally. In clinical studies, MEP has been proven to be safe and effective to help address the symptoms of oestrogen deficient skin and improve skin’s hydration, firmness, luminosity, and appearance of fine lines. MEP is a non-hormonal solution that provides benefits exclusively to the skin.
“There is a perception among women that ageing skin is a natural part of life and occurs as you age chronologically or through exposure to environmental factors such as sunlight and pollution. Oestrogen loss, however, is a key factor in accelerated facial ageing,” said NYC dermatologist Dr Diane Berson. “My patients with skin concerns, including dryness and ageing, don’t want the side effects sometime associated with other treatments for oestrogen deficiency. More importantly, these may not target the skin exclusively. I’m excited to be able to offer my patients a new solution that is safe and effective.”
The Emepelle range
The Emepelle® product line consists of a serum and a night cream. The Emepelle® Serum and Night Cream feature MEP Technology and are further fortified with other proven ingredients to help provide additional anti-aging benefits. The products work on all skin types and are recommended for women who are in perimenopause or menopause.
Emepelle is distributed in Australia and New Zealand by Dermocosmètica. For stockist information contact info@dermocosmetica.com.au.
1 Draelos, ZD. A double‐blind randomized pilot study evaluating the safety and efficacy of topical MEP in the facial appearance improvement of Oestrogen deficient females. J Drugs Dermatol. 2018; 17(11): 1032‐1035. 2 Archer DF. Postmenopausal skin and Oestrogen. Gynecol Endocrinol. 2012;28(sup2):2‐6. 2. Hall G, Phillips TJ. J Am Acad Dermatol. 2005;53:555‐68. 3. Shu YY, Maibach HI. Am J Clin Dermatol. 2011;12:297‐311.
